6th Annual
Experimental Therapeutics in Oncology:
The Road to Personalized Medicine

Featuring the Fenmore Lectureship
and the Redlich Lectureship

November 3-4, 2017

COURSE DIRECTORS:
Monica Mita, MD, MSc • Alain C. Mita, MD, MSc • Robert Figlin, MD • Razelle Kurzrock, MD • Lawrence D. Piro, MD

FACULTY:
David D. Chang, MD, PhD • Ezra Cohen, MD • Barbara A. Conley, MD
Morganna Freeman, DO • Mark Goodman, MD, PhD • Omid Hamid, MD
Andrew E. Hendifar, MD, MPH • Edward S. Kim, MD • Michael Lill, MD
Nan Limvorasak, PharmD • Heather McArthur, MD, PhD • Ronald B. Natale, MD
Edwin M. Posadas, MD • Barry Rosenbloom, MD • Leanne Sakamoto, PharmD
Richard B. Schwab, MD • Steven Shiao, MD, PhD • Diane Simeone, MD

EXPLORE NEW AGENTS IN:
• Breast Cancer
• GI Malignancies
• Head and Neck Cancers
• T-Cell Therapeutics

Cedars-Sinai Medical Center
Harvey Morse Conference Center
Los Angeles, CA 90048

In collaboration with UC San Diego Moores Cancer Center

For the latest course information and to register, visit cedars-sinai.edu/oncolgycme
COURSE DESCRIPTION AND STATEMENT OF NEED
This important educational activity will provide guidance to frontline and oncology clinicians, oncology nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists with the most current information available about new agents in oncology and the translation of the latest research to their patients. The 6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine conference will cover drug and treatment updates with a focus on new agents in breast cancer, GI malignancies, and head and neck cancers. The conference will also feature a mini-symposium that will cover various new clinical trials.

EDUCATIONAL OBJECTIVES
• Assess cancer immunotherapy treatments and their application in clinical practice, based on a thorough understanding of how they work, their side effects and indications for use
• Evaluate emerging clinical data for new agents and evolving strategies for the treatment of breast cancer, and develop individualized treatment plans for patients based upon an evaluation of efficacy and safety
• Evaluate clinical data and mechanism of action for newly approved drugs for treating cancer
• Use AJCC or other appropriate staging in clinical practice, including appropriate prognostic indicators and evidence-based national guidelines for treatment planning
• Recognize and describe the mechanism of action, efficacy and side effects of new treatment options for myeloma
• List and apply new treatment options for head and neck cancer

ACCREDITATION STATEMENT
Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Cedars-Sinai Medical Center designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES
The California State Board of Registered Nursing accepts courses approved by the ACCME for Category 1 credit as meeting the educational requirements for license renewal.

POLICY ON DISCLOSURE
It is the policy of Cedars-Sinai Medical Center to ensure balance, independence, objectivity and scientific rigor in all its educational activities. Cedars-Sinai Medical Center assesses conflicts of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter’s content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.

While Cedars-Sinai Medical Center endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
Commercial support for this conference is pending. Companies who support this CME activity with educational grants will be acknowledged at the conference.

SPECIAL ACKNOWLEDGMENT
Cedars-Sinai Medical Center also wishes to acknowledge the generosity of the Board of Governors Clinical Research Unit for its continuous support.

Cedars-Sinai also appreciates the support received from The Fenmore Lectureship and The Redlich Lectureship. The Fenmore Lectureship was initiated in 1978 by Maxwell J. Fenmore to present conferences on oncology. The first annual meeting was held in 1979. The Redlich Lectureship was initiated in 1980 by Freida K. and Max H. Redlich as an endowed lectureship in hematology to honor the outstanding CSMC medical staff and in particular the Division of Hematology/Oncology. In 1981, Mr. Redlich passed away from a rare hematological disorder.
FRIDAY, NOVEMBER 3, 2017

CO-CHAIRS: Monica Mita, MD; Ronald Natale, MD

1:30 P.M. Registration

2:00 Value-based therapeutics in oncology
Leanne Sakamoto, PharmD; Edwin Posadas, MD

2:30 Drug-drug interactions in oncology
Nan Limvorasak, PharmD

3:00 Immuno-oncology: Adverse events management
Morganna Freeman, DO

4:00 Integration of immune therapies and radiation oncology
Steven Shiao, MD, PhD

4:30 P.M. Reception

SATURDAY, NOVEMBER 4, 2017

CO-CHAIRS: Robert Figlin, MD; Razelle Kurzrock, MD

7:30 A.M. Registration

8:10 New drugs approved in 2016 and their mechanism of action
Alain Mita, MD

8:40 Q & A

MINI-SYMPOSIUM: BIG STUDIES, BIG DATA?

8:50 Precision promise
Diane Simeone, MD

9:10 Redlich Lecture: Tapur
Edward Kim, MD

9:30 NCI-Match
Barbara Conley, MD

9:50 DART
Razelle Kurzrock, MD

10:10 I Spy
Richard Schwab, MD

10:30 Q&A

10:40 Break

11:00 Personalized medicine for GI malignancies: Harnessing Her2/Neu, BRAF and MSI
Andrew Hendifar, MD

11:40 Q&A

11:50 New therapeutic approaches for melanoma
Omid Hamid, MD

12:10 P.M. Q&A

12:30 Lunch
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30</td>
<td><strong>KEYNOTE ADDRESS:</strong> T-cell therapeutics</td>
</tr>
<tr>
<td></td>
<td><em>David Chang, MD, PhD</em></td>
</tr>
<tr>
<td></td>
<td><em>(CME credit will not be provided for this talk)</em></td>
</tr>
<tr>
<td>2:20</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>2:30</td>
<td>Updates in new therapeutics for hematological malignancies</td>
</tr>
<tr>
<td></td>
<td><em>Michael Lill, MD</em></td>
</tr>
<tr>
<td>2:50</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>3:00</td>
<td><strong>Break</strong></td>
</tr>
<tr>
<td>3:15</td>
<td>Fenmore Lecture: Head and neck cancer updates</td>
</tr>
<tr>
<td></td>
<td><em>Ezra Cohen, MD</em></td>
</tr>
<tr>
<td>3:45</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>3:55</td>
<td>HPV-related malignancies</td>
</tr>
<tr>
<td></td>
<td><em>Mark Goodman, PhD</em></td>
</tr>
<tr>
<td>4:15</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>4:20</td>
<td>Integration of immune therapies in the treatment of breast cancer</td>
</tr>
<tr>
<td></td>
<td><em>Heather McArthur, MD, PhD</em></td>
</tr>
<tr>
<td>4:40</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>4:45 P.M.</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
# 6th Annual Experimental Therapeutics in Oncology:
The Road to Personalized Medicine

**FRIDAY-SATURDAY, NOVEMBER 3-4, 2017**

## REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>PHYSICIAN</th>
<th>ALLIED HEALTH PROFESSIONAL</th>
<th>*RESIDENT/FELLOW</th>
<th>INDUSTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Received by October 23, 2017</td>
<td>$155</td>
<td>$85</td>
<td>free</td>
<td>$200</td>
</tr>
<tr>
<td>Received after October 23, 2017</td>
<td>$195</td>
<td>$95</td>
<td>free</td>
<td>$225</td>
</tr>
</tbody>
</table>

Residents/Fellows are eligible to attend for a reduced registration fee. In order to receive this reduced fee, please send the written proof of residency (e.g., letter from Program Director) along with your completed registration form, or upload the written proof of residency online.

## REGISTRATION METHODS:

- **ONLINE** registration: cedars-sinai.edu/oncologycme
- **MAIL** form to: Cedars-Sinai Medical Center
  Office of Continuing Medical Education
  Attn: Registration
  8797 Beverly Blvd., Suite 250
  Los Angeles, CA 90048
- **FAX** form to: 310-423-8596

For additional course or registration information, call 310-423-5548.

Please print clearly

- LAST NAME ____________________________ FIRST NAME ____________________________
- DEGREE ____________________________ SPECIALTY ____________________________
- ADDRESS ____________________________
- CITY ____________________________ STATE __________ ZIP __________
- PHONE ____________________________ FAX ____________________________

* An email address is required to register for the conference.

CHECK ENCLOSED PAYABLE TO CSMC FOR $____________

PLEASE CHARGE MY CREDIT CARD

- [ ] VISA
- [ ] MASTERCARD
- [ ] AMEX FOR $____________

CC NUMBER ____________________________ CCV __________ EXP DATE ____/____

AUTHORIZED SIGNATURE ____________________________

**HOW DID YOU LEARN ABOUT THIS CME ACTIVITY?**

- [ ] Brochure/Other Printed Materials
- [ ] Cedars-Sinai Website
- [ ] Email
- [ ] Internet Search
- [ ] Colleague
- [ ] Past Participant
- [ ] Internal Cedars-Sinai Communication
- [ ] Other ____________________________

**REFUND POLICY**

All cancellations must be submitted in writing, and refunds will be subject to a $50 administrative charge. No refunds will be given after October 25, 2017. Please e-mail cancellation requests to cme@cshs.org. If you do not receive confirmation of your cancellation via e-mail, please call 310-423-5548.

**CANCELLATION POLICY**

Cedars-Sinai reserves the right to cancel or reschedule programs due to circumstances beyond its control, or to close registration when programs are oversubscribed. Registrants are advised against purchasing nonrefundable airline tickets until they receive registration confirmation. Cedars-Sinai is not responsible for penalties incurred as a result of cancelled transportation costs.
FACULTY

*Alain C. Mita, MD
Course Co-Director
Co-Director, Experimental Therapeutics Program
Associate Professor, Department of Medicine
Division of Hematology/Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai
Los Angeles, CA

*Monica Mita, MD
Course Co-Director
Co-Director, Experimental Therapeutics Program
Associate Professor, Department of Medicine
Division of Hematology/Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai
Los Angeles, CA

Lawrence D. Piro, MD
Guest Course Co-Director
Hematology/Oncology
President and CEO of The Angeles Clinic and Research Institute
Los Angeles, CA

*Robert A. Figlin, MD, FACP
Course Co-Director
Steven Spielberg Family Chair in Hematology/Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai
Los Angeles, CA

Razelle Kurzrock, MD
Course Co-Director
Chief, Division of Hematology & Oncology
Murray Professor of Medicine
Senior Deputy Director, Clinical Science
Director, Center for Personalized Cancer Therapy & Clinical Trials Office
UC San Diego Moores Cancer Center
La Jolla, CA

*Steven Piantadosi, MD, PhD
Planning Committee
Experimental Therapeutics Program Associate
PHASE ONE Foundation Distinguished Chair
Director, Samuel Oschin Comprehensive Cancer Institute
Professor, Department of Medicine
Division of Hematology/Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

*Jaime Richardson
Planning Committee
Clinical Research Specialist
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

David D. Chang, MD, PhD
Executive Vice President, Research & Development, Chief Medical Officer
Kite Pharma
Santa Monica, CA

Barbara A. Conley, MD
Associate Director, Cancer Diagnosis Program (CDP)
Division of Cancer Treatment and Diagnosis (DCTD)
National Cancer Institute
Rockville, MD

*Omid Hamid, MD
Chief, Translational Research and Immunotherapy
Director, Melanoma Therapeutics
The Angeles Clinic and Research Institute
Los Angeles, CA

*Andrew E. Hendifar, MD, MPH
Co-Director, Pancreas Oncology
Gastrointestinal and Neuroendocrine Malignancies
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Michael Lill, MD
Director, Stem Cell and Bone Marrow Transplant Program
Professor, Medicine
Cedars-Sinai Medical Center
Los Angeles, CA

*Nan Limvorasak, PharmD
Clinical Pharmacist
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

*Heather McArthur, MD, PhD
Medical Director, Breast Oncology
Staff Physician
Division of Hematology Oncology
Samuel Oschin Comprehensive Cancer Institute
Acting Associate Professor of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA

*Ronald B. Natale, MD
Assistant Clinical Professor, Medicine
Medical Director, Clinical Lung Cancer Program
Cedars-Sinai Medical Center
Los Angeles, CA

*Samuel Oschin Comprehensive Cancer Institute Member
ACTIVITY DETAILS

CONFERENCE LOCATION
Cedars-Sinai Medical Center
Harvey Morse Conference Center
Plaza Level, South Tower
8701 Gracie Allen Drive
Los Angeles, CA 90048

PARKING
Self-parking is available in the visitor parking lots P1, P2 (George Burns Road) or P4 (Sherbourne Drive).

HOTEL ACCOMMODATIONS
For a detailed list of hotels convenient to the medical center, please visit cedars-sinai.edu/visitors, select Lodging, Dining, Services from the bottom of the page, continue to Where to Stay and select Find Lodging.

When making reservations at any of these hotels, please be sure to mention that you are attending a conference at Cedars-Sinai to ensure you receive the best current reservation rate.
Register now for:

6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine
FRIDAY-SATURDAY, NOVEMBER 3-4, 2017
CEDARS-SINAI

EXPLORE NEW AGENTS IN:
• Breast Cancer
• GI Malignancies
• Head and Neck Cancers
• T-Cell Therapeutics

Earn up to 8.5 AMA PRA Category 1 Credits™